{
    "nct_id": "NCT03674567",
    "official_title": "Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer",
    "inclusion_criteria": "* Documented advanced or metastatic cancer ineligible for standard therapies with one of the following histologies\n\n  * Dose Escalation: non-small cell lung cancer, head and neck squamous cell carcinoma, nasopharyngeal carcinoma, metastatic triple negative breast cancer, urothelial carcinoma, gastric cancer, esophageal carcinoma, cervical cancer, classical Hodgkin lymphoma\n  * Dose Expansion: nasopharyngeal carcinoma, lymphoma, head and neck squamous cell carcinoma, cervical cancer, non-small cell lung cancer, triple-negative breast cancer\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n* Evaluable disease at baseline (at least one measurable target lesion by imaging for expansion cohorts)\n* Tumor available for biopsy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of allergy or severe hypersensitivity to biologic agents\n* History of Grade 3-4 immune-related adverse events leading to discontinuation of prior immuno-oncology treatment\n* Active autoimmune disease or serious autoimmune disease within past 2 years requiring systemic therapy\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, (non-infectious) pneumonitis that required steroids, or symptoms of active pneumonitis\n* Prior allogeneic hematopoietic stem cell transplant within 5 years, or prior allogeneic organ transplant\n* Active graft-versus-host disease",
    "miscellaneous_criteria": ""
}